# A Study to Compare the Pharmacokinetics, Safety and Tolerability Between Fixed-Dose Combination and Co-Administration of HGP0904, HGP0608 and HCP1306 Tablets in Healthy Male Subjects.

> **NCT04322266** · PHASE1 · COMPLETED · sponsor: **Hanmi Pharmaceutical Company Limited** · enrollment: 61 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** HCP1701
- **DRUG:** HCP1306
- **DRUG:** HGP0904
- **DRUG:** HGP0608

## Key facts

- **NCT ID:** NCT04322266
- **Lead sponsor:** Hanmi Pharmaceutical Company Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-12-21
- **Primary completion:** 2019-02-13
- **Final completion:** 2019-02-13
- **Target enrollment:** 61 (ACTUAL)
- **Last updated:** 2020-03-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04322266

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04322266, "A Study to Compare the Pharmacokinetics, Safety and Tolerability Between Fixed-Dose Combination and Co-Administration of HGP0904, HGP0608 and HCP1306 Tablets in Healthy Male Subjects.". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04322266. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*